Exploring neoadjuvant therapy for lung cancer
Official title: Exploring the Frontiers of Neoadjuvant Therapy for Lung Cancer: a Prospective Observational Real-world Study
Run by Shanghai Pulmonary Hospital, Shanghai, China · NCT06216782 · Data updated 2026-11-12
This study is testing how well different treatments before surgery, like chemotherapy and immunotherapy, can help people with lung cancer and what factors might affect their success.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 2000 (estimated) |
| Sponsor | Shanghai Pulmonary Hospital, Shanghai, China Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Status | Recruiting |
| Started | December 16, 2023 |
| Main results expected | December 30, 2033 |
| Study ends | December 30, 2033 |
| Registry record updated | January 22, 2024 |
| Trial ID | NCT06216782 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older with a confirmed diagnosis of non-small cell lung cancer or small cell lung cancer who have received neoadjuvant therapy.
✕Probably not a fit
Patients currently enrolled in other clinical trials or those who refuse follow-up may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to evaluate the effectiveness of various neoadjuvant therapies, including chemotherapy, immunotherapy, and targeted therapy, in patients with lung cancer. It focuses on understanding how different patient characteristics influence treatment outcomes and the long-term survival rates associated with these therapies. By analyzing real-world clinical data, the study seeks to identify the strengths and weaknesses of different neoadjuvant regimens in improving surgical resection rates and overall therapeutic effects.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies that enhance survival rates for lung cancer patients.
How similar studies have gone: Previous studies have shown promising results with neoadjuvant therapies in lung cancer, indicating potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age greater than or equal to 18 years; 2. Pathohistologically confirmed diagnosis of non-small cell lung cancer or small cell lung cancer; 3. Received neoadjuvant therapy after diagnosis; 4. Written informed consent. Exclusion Criteria: 1. Patients enrolled in other clinical trials; 2. Patients refused enrollment in this study; 3. Patients refused follow-up.
Where it's running
-
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China Recruiting
Study contacts
- Principal investigator: Peng Zhang, Ph.D. — Shanghai Pulmonary Hospital, Shanghai, China
- Study coordinator: Peng Zhang, Ph.D.
- Email: zhangpeng1121@tongji.edu.cn
- Phone: 021-55672180
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
ePRO in advanced lung cancer: emotional distress, brain metastasis, and symptom burden
This study tests how patients with advanced lung cancer—some with brain metastases—report emotional distress and symptoms over time using electronic questionnaires.
-
Urine VOC Test to Detect Lung Cancer in Never Smokers
A urine test that looks for volatile compounds is tested to see if it can help detect lung cancer in adults who have never smoked.
-
SI-B036 safety test in advanced and metastatic solid tumors
This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.
-
Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment
This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.
-
ENPP1/cGAS and FAP in Solid Tumors in Vietnamese Patients
This Vietnam-based study will test ENPP1, cGAS, and FAP expression in archived tumor samples from Vietnamese adults with solid cancers using immunohistochemistry.
-
Olive oil before lung cancer surgery to see if it lowers chylothorax
This study tests whether drinking 40 mL of extra-virgin olive oil a few hours before lung cancer surgery can reduce chylothorax after tumor removal.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.